Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks for sharing.
Please check in more often. It's good for my HBP
IMO he should do his job and not send out any more big words to appease investors who have no patience. You can't talk the PPS up. Results counts and results take time. Unfortunately, Leo has earned a reputation of a big mouth through years of PR's calling out to Obama and promising momentous months here and there. I'm perfectly happy with the science and the way it progresses and I don't need Leo to come running with a PR every time the PPS fluctuates. I want him to advance the pipeline and report back to us in a more stringent and mature manner. I'm pretty sure that is what we will see from here as he has probably learned his lesson.
Results count and we will get them.
GO CTIX
Sounds very promising. Thank you very much for your insight.
Sounds great. Thanks a lot.
OK, thanks. And sorry for not seeing your first post. I'd very much like an eye specialist to chime in. CTIX and AVRO must see something very promising. Otherwise it seems odd to present.
So much exciting stuff going on with CTIX on so many levels and in so many areas.
F
Has the company talked about the ARVO conference that takes place in Denver,CO starting Sunday ?
Brilacidin is being presented tomorrow morning at 8.30:
C0149: The In Vitro and In Vivo Antibacterial Evaluation of Brilacidin
Exhibit Hall
193664
8:30am - 10:15am
Sun, May 03
Regis Kowalski
The Charles T. Campbell Lab - UPMC
From the website:
The Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) is the largest gathering of eye and vision researchers in the world, attracting over 11,000 attendees from more than 75 countries. About 45% of our attendees are from outside the U.S.
http://www.arvo.org/Annual_Meeting/Program/
Thank you so much for your contributions to this board. You're the voice of reason.
2 x ph3 trial start September 2015 with 3 months recruitment. Study completion March 2016, data collection and analysis and we will be at July 2016 before Leo can ask for pre-NDA meeting w/ FDA. Meeting in September at the earliest. Time to complete dossier at least 3 months. More likely 6. Earliest possible PDUFA in this scenario is September 2017. I will be totally fine with this scenario as things take time. IMO and I'm most certainly wrong. GLTA
And with Mepact only approved in Europe there is a great need for a treatment beyond chemo for this particular cancer.
WSJ article. I hadn't seen it before. Sorry if it has already been posted here.
http://www.wsj.com/articles/BL-DFB-22584
Believe It or Not, Boeheim’s Stock Is Soaring
Syracuse coach Jim Boeheim during the Orange’s loss at N.C. State on Saturday.
Associated Press
Jim Boeheim’s legacy took a hit last week when the NCAA imposed sweeping sanctions on his Syracuse basketball program, alleging rule violations over the last decade.
But the stock of a Boeheim side venture is rising.
Boeheim is an adviser to Cellceutix Inc., a Boston-area biopharmaceutical firm working to develop drugs for cancer and other diseases. In the last year, Cellceutix’s stock has more than doubled. Shares are up fivefold since Boeheim joined the company in the spring of 2012, at which time he received company stock as his only compensation, according to Cellceutix chief executive Leo Ehrlich, who didn’t specify the number of shares given to Boeheim. Since the granting of those shares, Boeheim has received no compensation, Ehrlich said.
Syracuse didn’t respond to a request for comment from Boeheim.
Ehrlich said Tuesday in an email that Boeheim, a survivor of prostate cancer, has helped bring attention to the company, in addition to “offering general advice” on development of cancer treatments and other drugs and supporting the company’s efforts to list on Nasdaq, something Ehrlich hopes to accomplish by year’s end. “He has been a tremendous asset,” Ehrlich said.
Cellceutix generates no revenue and has yet to send a drug to market. The company’s cornerstone cancer drug candidate, Kevetrin, is undergoing clinical trials. Its top two executives are the only members of its board. As a company traded only over-the-counter, it isn’t followed by industry analysis.
The company’s soaring stock price has generated lively debate on investor blogs, including an exchange on Seeking Alpha in which contributors contend that the company is either over- or undervalued by “at least 90%.”
RELATED:
Please excuse if this has been posted before.
http://www.microcapdaily.com/shorts-failed-on-cellceutix-corp-otcmktsctix/19263/
Shorts Failed on Cellceutix Corp (OTCMKTS:CTIX) 0
BY PAUL KNAG ON MARCH 3, 2015 MICRO CAP INSIDER, SMALL CAPS
Cellceutix Corp (OTCMKTS:CTIX) moves up again on accelerating volume off its $3.50 base. CTIX is in the midst of a spectacular move up from pennies a few years ago. In January the stock dipped below $3 on a significant short attack.
The shorts continue to threaten to attack with two misleading Seeking Alpha articles came out. According to available information CTIX had 1.2 million shares short around November 28, a number that increased to a staggering 5.9 million shares short by December 15. The massive increase in the short position is timed perfectly for the false and misleading articles from Seeking Alpha. Any attempts to short CTIX have been met with failure and now CTIX is moving up again on accelerating volume.
CTIX is one of those legendary stories that we love to report on; it all comes back to Cellceutix chief scientific officer, Dr. Krishna Menon; the man is a real whiz; he played key roles in developing two blockbuster cancer drugs; Gemzar and Alimta for Eli Lilly & Co.(NYSE:LLY) back in the late 90’s.
For CTIX he developed Kevetrin which is currently in Phase 1 clinical trial at Harvard Cancer Centers’ Dana Farber Cancer Institute. Kevetrin is successful in regulating the p53 pathway that has long been the holy grail of cancer research and big pharma. Industry leaders spent hundreds of millions of dollars trying to achieve what Dr. Krishna Menon has achieved with Kevetrin.
Cellceutix Corp (OTCMKTS:CTIX) is a clinical stage biopharmaceutical company located in Beverly, Massachusetts developing innovative therapies in oncology, dermatology and antimicrobial applications.
CTIX flagship is Brilacidin, a new class of antibiotics called defensin-mimetics, which are modeled after host defense proteins. These are the “front line” of defense in the human immune system and mange suggest Brilacidin could rival Cubist’s (NASDAQ:CBST) Daptomycin as the antibiotic of primary choice.
CTIX announced today that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation for Brilacidin as a new treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) ahead of its meeting this month with Cellceutix regarding Cellceutix’s planned Phase 3 trial of Brilacidin for ABSSSI. Brilacidin, the Company’s lead drug in a new class of antibiotics called defensin-mimetics, completed a Phase 2b trial in September showing, amongst other things, a single dose of Brilacidin to be as effective in treatment of ABSSSI as a FDA-approved seven-day dosing regimen of daptomycin.
It's not unheard of to uplist and announce additions to the BOD simultaneously.
A recent example which resembles the position of CTIX somewhat:
DALLAS, Feb. 12, 2015 (GLOBE NEWSWIRE) -- Natural Health Trends Corp. (NHTC), a leading direct selling company that markets premium quality personal care, wellness and "quality of life" products under the NHT Global brand, today announced that its shares of common stock have been approved for listing on the Nasdaq Capital Market. Trading on the Nasdaq Capital Market is expected to commence on Tuesday, February 17, 2015, and the Company's common stock will continue to trade under the symbol "NHTC." The Company's common stock will remain on the OTCQB until it transitions to Nasdaq.
In connection with the Company's Nasdaq listing approval, the Company's Board of Directors was expanded to provide for five directors, and Kin Y. Chung and Christopher R. O'Brien were elected to fill the newly-created vacancies. Mr. Chung is recently retired from Bioherb Technology Company, Ltd., a private Hong Kong company that served as an importing company for food and food manufacturing products, which Mr. Chung founded and for which he served as President. Mr. O'Brien is a principal with the national law firm, Polsinelli LLP, where he specializes in corporate law. Both Messrs. Chung and O'Brien qualify as "independent directors" under the Nasdaq Marketplace Rules.
"We are honored to be uplisted to the Nasdaq Capital Market and to add Messrs. Chung and O'Brien to our Board," commented Chris Sharng, President of Natural Health Trends Corp. "The transition to Nasdaq underscores the strength of our business as a global provider of premium personal care, wellness and 'quality of life' products. We believe this move will support our evolution as a public company, increase our visibility to the institutional investment community, provide greater access to capital, enhance trading liquidity of our common stock and broaden awareness of our brand." Mr. Sharng added that, "Kin Chung and Chris O'Brien bring outstanding backgrounds and experience to our Board, and I have no doubt they will make important contributions to the Company."
In addition to the cash compensation payable to Messrs. Chung and O'Brien in their capacity as non-employee directors of Natural Health Trends Corp., they each were granted 3,058 shares of the Company's restricted stock. These shares of restricted stock will vest on a quarterly basis over a three-year period. The grant of shares of restricted stock to the Company's non-employee directors is designed to further align the interests of the Company's directors and stockholders.
Don't worry. Retrophin is selling to avoid bankruptcy. If you are accumulating now is the time to buy.
My faith in CUV has never been stronger. I'm accumulating and pretty sure this is a second in a life time investment. Second, because CTIX shares the gold medal with CUV.
Thanks for posting this. It's a great reminder. Or eye opener if you have recently invested.
Thanks for posting. This being a type B meeting I think we can assume that we will get news about the actual result of the meeting + 90 days from now. When Leo asks for the meeting the FDA has 21 days to schedule and the meeting has to take place within 60 days from the request. Then, the FDA has 30 days to forward the minutes to CTIX and then we will know for sure what's in store for a Phase 3. Even though Leo is likely to post updates along the way, the minutes is what I'm looking for. It's going to be a hot summer. Go CTIX.
I'd say August as well. But since it's biotech I'll ad a month. And then a month more to be on the safe side. October 2015 is my bet.
Definitely only in the "nice to have" category of PR's. Looking forward to some "need to have."
Thanks. Very well written. I'm not in Denmark, though, but in the US. Maybe The Dane has contacts in Denmark ? My contact has Scandinavian roots and it made it easier to navigate the different sites.
Should we let someone with a scientific background send the email ? I could do it, but the impact might be bigger if the sender is an md, phd etc.
Danish media blitz: I've found some direct email addresses to some of the media outlets in Denmark who seem to cover life science and pharma. Who wants to put together a "PR" on Brilacidin and the ECCMID ?
Here's the list:
Dagens Medicine. Seems to cover pharma, life science and the public health care system in Denmark. Email: nyheder@dagensmedicin.dk
Ugeskrift for lager: A more specialized magazine for GPs and doctors. Email: presseufl@dadl.dk
MedWatch: An online news service about biotech and life science.
Email: medwatch@medwatch.dk
Then there are a lot of newspapers, but I think we would have to write directly to the reporters who cover pharma and not a main postbox that's flooded daily with dubious newsletters. I'll try to compile another list.
And if George W. Bush invested in CTIX: Either you're with us or you're against us.
An observation regarding Kevetrin:
If you Google MD Anderson and Kevetrin the first hit will be this page:
http://www.mdanderson.org/patient-and-cancer-information/cancer-information/cancer-types/retinoblastoma/
Interesting, because the page itself doesn't mention Kevetrin at all. In fact, nowhere on the MD Anderson site is Kevetrin to be found if you do a search.
Most likely, that means that MD Anderson themselves included the word Kevetrin somewhere hidden in the source for the retinoblastoma site so that the search engines would in fact lead to that specific site.
Talk about 3rd party validation if that is in fact so.
Yes, a writer or a journalist would be great. Do we have one on this board ? Or would someone take on the task to write a short and compelling story about CTIX, Brilacidin and why it's he main attraction at the ECCMID ?
Copenhagen: I'm working (with a European friend) to gather a list of
possible news outlets in Denmark who could be likely to cover
the ECCMID in April. Does anyone want to help putting together an easy read presentation of Brilacidin and why Leo and Co. should be
on the front pages ?
Regards,
Farmazutical Inc.
Specialized (but not certified) CTIX Media Bureau
OK. Thanks. Also for private replies. I don't have that option but maybe I should get it in order to be able to discuss the dark side in private Totally agree that it's important to keep the forum clean from all that garbage you see elsewhere. Just thought that it might be a little over the top.
Yes. I should have read the qualifying requirement more throughly. I see that now. Thanks !
Missed that one. Thanks. Looks like we have the book value to qualify for the lower closing price option.
Great start of the week this is.
Wonderful. Thanks for sharing ! But we will still need to trade above $4 for 90 consecutive days before uplisting to NCM.
I think Copenhagen will be the big catalyst that will make all this possible.
Couldn't it be that all the recent positive news will lead to something that will make up-listing possible ? Hence, it's not the news itself but the possible partnership that will materialize because of said news ?
Drugmakers get invitation to WH. Next time I talk to Barack I'll let him know that he should have Leo on the guest list.
The heads of research at several large drugmakers have received mysterious invitations to the White House for a meeting Friday morning, where more details are expected to be shared on President Barack Obama's plans for the "precision medicine" initiative he mentioned in his State of the Union address.
Vertex, Regeneron and Merck have all received invitations from the Office of Science and Technology Policy, asking for their top researchers to attend the event. Other details weren't shared in the invitation, a copy of which was obtained by CNBC.
The White House didn't immediately respond to a request for more information.
I wonder if CTIX is in contact with the EMA (and maybe ANVISA) about this. If CRE spreads through athletes, sailors etc. this will be a world wide problem.
Does anyone know if CRIX plans to address the European market as part of the 1. wave or will EU approvals be sought only after FDA approval(s) ?
Regarding the Rio angle. I appreciate that it could be a major achievement and very beneficial for CTIX if they could have a compound ready to fight
the carbapenem resistant klebsiella pneumoniae that the Brazil Health authorities fear will pose a threat to the Olympics.
But that's not even two years from now. How would that be possible to get a drug through trials and approval in due time ?
Would this compound be able to go directly to Phase 2 because it derives from the same platform as Brilacidin or is a Phase 1 required ?
Even if the skip Phase 1 I find it overly optimistic that this drug should be ready for the Olympics next year.
It is very possible that it could be ready in 2-3 years I think and that's good enough for me.
Full trust should never be given unless you have chosen to treat management as Gods.
I have to admit that Leo is very thorough and respectful when answering shareholder emails. I respect that a lot.
Ok. I would like meat. Not that I'm not overall positive and still holding but I'm getting hungry. And I would prefer less volatility.
It pretty clear that no matter what PR Leo sends out from now on it will make the pps go down if the news is only about intentions to do this and that. Most other companies would surge on today's PR. But because we have had way too many PRs announcing what might happen I guess the market is fed up or bored. We want meat on the dish.
I agree. I just hope we'll have no more PRs before there is something very substantial and material to report. Not "going to happen" but "this actually happened" news.
Kevetrin is the perfect candidate for BTD and I believe things can evolve very quickly if the later cohorts produce stage 4 patients with disappearing tumors. Ethically, it would be a crime to limit access to Kevetrin - especially for Stage 4 patient for whom no other options exist. With rolling review etc. I think Kevetrin could be partly approved within very few months / years.
I think the risk is very real but I don't hope it will happen. I'm in this to sell above $50. A buyout at $10 or $15 would be extremely disappointing. I don't think, however, that Wolgen and Co. have spent so many years on Scenesse to just sell the company. Wolgen wants to own a soccer team. He won't be able to buy more than a sh!tty German 3rd league team if he sell for $15.
When you look at the number of oral presentations on the ECCMID website you could fear that CTIX risks to gain only little attention.
I think we should consider putting together a well written "PR" and send it to all the relevant Danish media outlets prior to the conference. I have a Scandinavian friend who could help compiling a list of the email addresses we would need and all relevant twitter accounts. There must be a number of medical journals, business newspapers and TV networks who would love to report on the big story from the ECCMID. They just need to be pointed in the right direction.